Notice of Proposed Sale · 144
Bicara Therapeutics Inc.
BCAXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Bicara Therapeutics Inc.
- Issuer CIK
- 0002023658
- SEC file number
- 001-42271
- Phone
- 617-468-4219
- Person for whose account securities are to be sold
- Mazumdar Claire
- Relationships to issuer
- Officer · Director
- Street
- 116 HUNTINGTON AVENUE SUITE 703
- City
- BOSTON
- State / country code
- MA
- Postal code
- 02116
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 10,000 | 296,800.00 | 65,703,866 | 07/10/2026 | NASDAQ | UBS Financial Services, Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- UBS Financial Services, Inc.
- Street
- 11 Madison Ave
- Street (continued)
- 4th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10010
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 07/10/2026 | Exercise of stock options | Issuer | 10,000 | N | 07/10/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Claire Mazumdar | Common | 05/18/2026 | 15,000 | 300,577.50 |
| Claire Mazumdar | Common | 04/20/2026 | 15,000 | 354,145.50 |
Seller — prior-sale row 1, entry 1
- Name
- Claire Mazumdar
- Street
- 16 HUNTINGTON AVENUE SUITE 703
- City
- Boston
- State / country code
- MA
- Postal code
- 02116
Seller — prior-sale row 2, entry 1
- Name
- Claire Mazumdar
- Street
- 16 HUNTINGTON AVENUE SUITE 703
- City
- Boston
- State / country code
- MA
- Postal code
- 02116
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 07/10/2026
- Signed
- /s/ UBS Financial Services Inc., as attorney-in-fact for Claire Mazumdar
- Plan adoption dates
- 03/31/2026
Recent company filings
- SCHEDULE 13G/A - filed by T. Rowe Price Investment Management, Inc. regarding Bicara Therapeutics Inc.Oct 7, 2026
- Entry into a Material Definitive AgreementAug 25, 2026
- 4 filingAug 14, 2026
- SCHEDULE 13G/A - filed by Janus Henderson Group Ltd. regarding Bicara Therapeutics Inc.Aug 13, 2026
- S-8 filingAug 11, 2026